Moneycontrol PRO
HomeNewsTrendsCoronavirus pandemic | India will continue HCQ treatment for mild COVID-19 cases

Coronavirus pandemic | India will continue HCQ treatment for mild COVID-19 cases

Health ministry officials, Indian Council of Medical Research (ICMR) experts, and the Drug Controller General of India have collectively reviewed the novel coronavirus clinical management protocol and decided to limit HCQ use to moderate patients.

June 17, 2020 / 13:38 IST
Hydroxychloroquine (Image Source: Reuters)

Despite the US Food and Drug Administration discontinuing the use of hydroxychloroquine (HCQ) for novel coronavirus treatment, India has decided to continue using the prophylactic. Indian health authorities argued that the decision to use the drug to treat mild COVID-19 patients is based on “risk-benefit assessment” and will not be withdrawn just because the FDA has.

Malaria drug HCQ, which is used in lupus and rheumatoid arthritis treatment at present, has had the world divided over its use in COVID-19 treatment.

For live updates on coronavirus, click here

An Economic Times report quoting a senior official from the drug controller’s office, stated: “We have just changed the clinical management guidelines last week. We are not considering any changes just because the US FDA has withdrawn the emergency use for HCQ.”

However, health ministry officials, Indian Council of Medical Research (ICMR) experts, and the Drug Controller General of India have collectively reviewed the novel coronavirus clinical management protocol and decided to limit HCQ use to moderate patients. They also advised avoiding the use of the drug to treat patients with “severe diseases”.

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

Backing the need for the review, another government official said it was necessary “because of growing evidence on the drug”.

To follow our full coverage on coronavirus, click here

Moneycontrol News
first published: Jun 17, 2020 01:38 pm

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Subscribe to Tech Newsletters

  • On Saturdays

    Find the best of Al News in one place, specially curated for you every weekend.

  • Daily-Weekdays

    Stay on top of the latest tech trends and biggest startup news.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347